Tumori (TUMORI )

Publisher: Istituto Nazionale per lo Studio e la Cura dei Tumori (Milano)


  • Impact factor
    Hide impact factor history
    Impact factor
  • 5-year impact
  • Cited half-life
  • Immediacy index
  • Eigenfactor
  • Article influence
  • Website
    Tumori website
  • ISSN
  • OCLC
  • Material type
    Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Ameloblastic carcinoma is a rare malignant odontogenic tumor and is considered as the malignant counterpart of ameloblastoma with features of both benign and malignant histology. It may arise de novo or from a long-standing ameloblastoma and is locally aggressive with a propensity for metastasis. With limited documentation, little is known about its pathobiogenesis, with no universal guidelines for management. For clinicians, differentiating ameloblastic carcinoma from ameloblastoma and malignant ameloblastoma in a patient presenting with a suspicious jaw tumor is a challenge due to overlapping clinical features, inconclusive cytology/biopsy reports, different management approaches and inadequate follow-up. Proper knowledge of the disease entity and a high index of suspicion are essential. Here we elaborate the dilemmas in diagnosis and management of ameloblastic carcinoma through presentation of a representative case in a 56-year-old man presenting with a tumor in the mandible.
    Tumori 10/2014; 100(5):e189-96.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. Breast cancer treatment currently represents one of the biggest chal- lenges in clinical oncology. The gold standard for axillary lymph node management is to perform sentinel node biopsy to avoid axillary dissection and its sequelae. The de- tection of radiocolloid flow outside the axillary nodes is a diagnostic and therapeutic challenge. Methods. A database search at the Department of Oncology of Palacky University, Olomouc, Czech Republic, identified 127 patients who underwent breast cancer re- section with a sentinel node procedure and had radiocolloid flow into the internal mammary nodes. Sentinel node lymphoscintigraphy was performed after intra- parenchymal injection. Clinical and pathological data were collected to identify pos- sible risk factors. Results. Ten clinical and pathological parameters including age, tumor histology, ax- illary lymph node status, estrogen receptor expression, progesterone receptor ex- pression, tumor grade, Ki-67 expression, Her-2 status, tumor size and tumor location were analyzed with regard to internal mammary node drainage. A cohort of 127 pa- tients with detected drainage into the internal mammary nodes was compared with 135 patients without such drainage. Six significant risk factors, including age <50 ye- ars (P <0.0313), tumor location in central and inner quadrants (P <0.012), larger tu- mor size (P <0.017), positive Her-2 status (P <0.025), progesterone receptor expres- sion (P <10-4) and axillary lymph node involvement (P <0.01) were found to predict ra- diocolloid flow into the internal mammary nodes. Conclusion. Six parameters (patient age, tumor location, hormone receptor status, tumor size, Her-2 status and axillary lymph node status) should be considered in the management of breast cancer patients and help in the selection of patients for lo- coregional procedures encompassing the internal mammary nodes.
    Tumori 07/2014; 100:254-258.
  • Tumori 12/2013; 99.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims and background. To investigate the efficacy and tolerability of biweekly scheduled triplet chemotherapy consisting of gemcitabine, cisplatin and vinorelbine for chemotherapy-naïve advanced non-small cell lung cancer. Methods and study design. Patients with stage IIIB/IV non-small cell lung cancer and performance status of 0-2 were eligible. Patients who had brain metastasis and of an older age were also enrolled in the study. The triplet combination chemotherapy consisted of gemcitabine, cisplatin and vinorelbine at the doses of 1000 mg/m2, 25 mg/m2 and 50 mg/m2, respectively, were administered on day 1 and 14, every 28 days, up to 6 cycles. Results. Thirty patients were enrolled in the study. Median age was 60 years (range, 42-74). Most of the patients (83%) had metastatic disease and 7 patients (23%) had brain metastasis. In assessing 24 patients for response evaluation, none had complete response. Partial responses were achieved in 18 (60%) patients. Four patients (13%) had stable disease and 2 (7%) progressed. Thirteen percent and 20% of the patients developed severe (grade 3-4) neutropenia and anemia, respectively. Febrile neutropenia, severe thrombocytopenia, hepatic and renal toxicity were not seen. Overall and progression-free survival were 8.15 and 7.15 months, respectively. Patients who had no brain metastasis ( P = 0.069), who had more than 3 courses of chemotherapy (P <0.001), and who had chemotherapy applied without dose reduction (P = 0.018) had better survivals. Conclusions. The biweekly schedule of the triplet chemotherapy combination including gemcitabine, cisplatin and vinorelbine was effective in advanced, mostly metastatic non-small cell lung cancer with acceptable and manageable side effects.
    Tumori 07/2013; 99(4):463-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The case of a 72 year old woman with primary malignant melanoma of the esophagus, subjected twice to surgical operation with a 17-month interval and still alive 35 months after the onset symptoms is reported. In order to outline the biologic behaviour of this rare neoplasm, 44 similar bibliographic cases are analysed and comparisons made between melanoma and carcinoma of the esophagus as well as between melanomas of the esophagus and of the skin.
    Tumori 06/2013; 61(2):163-72.
  • Tumori 03/2013; 99(2):e55-60.
  • Tumori 01/2013; 99:e14-18.